CIP
ITCI

Chartwell Investment Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Chartwell Investment Partners’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$971K Buy
13,270
+105
+0.8% +$7.89K 0.03% 353
2024
Q2 		$902K Sell
13,165
-2,148
-14% -$149K 0.03% 355
2024
Q1 		$1.06M Buy
15,313
+3,682
+32% +$253K 0.04% 364
2023
Q4 		$833K Buy
+11,631
New +$669K 0.03% 375

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Chartwell Investment Partners's ITCI Position: Q3 2024 in Review

Chartwell Investment Partners increased its Intra-Cellular Therapies Inc. (ITCI) stake by 0.8% in Q3 2024, buying an estimated $7.89K and bringing the position to 13,270 shares worth $971K. The position accounts for 0.03% of the portfolio, ranked #353.

Chartwell Investment Partners first reported a position in ITCI in Q4 2023 and has held it in 4 quarters since. The position peaked at $1.06M in Q1 2024. 355 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

  • Chartwell Investment Partners held 13,270 shares of Intra-Cellular Therapies Inc. worth $971K as of Q3 2024.
  • Chartwell Investment Partners bought 105 Intra-Cellular Therapies Inc. shares in Q3 2024, an estimated $7.89K.
  • Intra-Cellular Therapies Inc. made up 0.03% of Chartwell Investment Partners's portfolio in Q3 2024, its #353 holding.
  • Chartwell Investment Partners first reported a position in Intra-Cellular Therapies Inc. in Q4 2023 and has held it in 4 quarters since.
  • Chartwell Investment Partners's Intra-Cellular Therapies Inc. position peaked at $1.06M in Q1 2024.
  • 355 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on Chartwell Investment Partners's 13F filing for Q3 2024, filed 4 Nov 2024.